

Millennium Biotechnologies, Inc Announces The Launch Of Its New Product Resurgex Select(TM) For The Oncology Market

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Sept. 16, 2005--Millennium Biotechnologies, Inc. is pleased to announce the development of its latest product to address the nutritional needs of those undergoing cancer treatments. This comprehensive, high protein, high calorie, whole foods based nutritional formula is designed to provide essential high quality nutrients in efforts as an alternative to the poor quality ingredient formulas presently on the market. The Company expects to commence marketing of Resurgex Select(TM) in the 4th quarter of 2005 in conjunction with its national sales launch into the oncology market with Cardinal Health.

Inadequate nutrient intake contributes to the nutritional decline in cancer patients which can impair their immune system, increase the risk of complications and impair treatment tolerance. For most patients, nutritional formulas may serve as the sole source of nutrition for those unable to consume an adequate diet. Nutritional support can assist in supporting immune function and promoting weight gain which can affect fatigue and quality of life in patients. "Unfortunately, not all calories are created equal. For the past several decades, many of the nutritional formulas offered utilize poor quality calories derived from sucrose, corn syrup and corn oil as major sources of calories." states Carl Germano, RD, CNS, CDN, Vice President of Research & Product Development for Millennium. "The development of Resurgex Select(TM) serves as the first alternative to these poor choices and utilizes calories from an array of healthier sources such as whey, oats, barley, brown rice, omega3's and fruit/vegetable extracts. In addition, Resurgex Select provides a full complement of essential vitamins and minerals and serves as an additional product addressing the nutritional needs of the oncology throughout their continuum of care."

It is important to understand that Millennium's strategy towards Resurgex Select as a significant nutritional support product in immunocompromised conditions follows the same thinking behind its flagship product Resurgex(R) - the provision of a multi component approach to address the multiple nutritional needs of the patient.

For additional information on the Resurgex product line, please contact Frank Guarino, Chief Financial Officer, at FGuarino@milbiotech.com or call (908) 604-2500.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(R) and RESURGEX Plus(R), are designed to assist in strengthening cellular defense and supporting the immune system in patients with HIV/AIDS, Hepatitis C, cancer and other chronic illnesses. Millennium Biotechnologies also owns the exclusive medical-market rights to GliSODin(TM) (SOD/gliadin), the only orally effective form of the important antioxidant SOD (superoxide dismutase). Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTC BB:MBTG.OB). For more information about Millennium Biotechnologies, please call (908) 604-2500 or visit www.milbiotech.com.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.